Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
211. |
ECCT/22/07/01 | GBT021601-021 Study A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Berhnards Ragama Ogutu 3. Videlis Nduba 4. Berhnards Ragama Ogutu Site(s) in Kenya 1. Gertude\'s Children\'s Hospital (Nairobi City county) 2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county) 3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county) 4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county) |
View |
212. |
ECCT/24/02/02 | Sabin 003 A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults |
Principal Investigator(s) 1. Prof. Videlis Nduba Nzioka Site(s) in Kenya KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya |
View |
213. |
ECCT/18/12/01 | study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants. A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya. |
Principal Investigator(s) 1. Mainga Hamaluba Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
214. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
View |
215. |
ECCT/14/02/03 | A Phase 1/2 Randomized, Double-Blind, Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus pneumoniae Whole Cell Vaccine Formulated with Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers (12-15 Months of Age) |
Principal Investigator(s) 1. Nekoye Namungu Otsyula 2. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kombewa Clinical Research Center |
View |